Orexo Unveils Promising Clinical Findings for OX640 at EAACI Congress 2025 in Glasgow Orexo announces its participation at the 2025 EAACI Congress, showcasing groundbreaking findings for OX640, a nasal treatment for severe allergic reactions.

Orexo Unveils Promising Clinical Findings for OX640 at EAACI Congress 2025 in Glasgow #Sweden #Orexo #AmorphOX #Uppsala #OX640

Orexo to Showcase Breakthrough Clinical Data for OX640 at the Upcoming EAACI Congress in Glasgow Orexo AB announces its participation at the EAACI Congress, presenting promising data for OX640, a nasal rescue treatment for severe allergies.

Orexo to Showcase Breakthrough Clinical Data for OX640 at the Upcoming EAACI Congress in Glasgow #Sweden #Orexo #Uppsala #OX640 #EAACI

Orexo's OX640 Clinical Study: Breakthrough Nasal Medication for Allergic Reactions Orexo has announced positive results from a clinical study of OX640, a nasal medication aimed at treating allergic reactions, promising rapid effectiveness.

Orexo's OX640 Clinical Study: Breakthrough Nasal Medication for Allergic Reactions #Sweden #Orexo #AmorphOX #Uppsala #OX640

Orexo's OX640 Clinical Study Shows Promise for Allergy Treatments with Rapid Effects Orexo's recent clinical trial for its nasal medication OX640 has shown encouraging results, indicating rapid absorption and effectiveness for allergy treatments.

Orexo's OX640 Clinical Study Shows Promise for Allergy Treatments with Rapid Effects #Sweden #Orexo #AmorphOX #Uppsala #OX640